TISIDB

Summary
Symbol	SELP
Name	selectin P (granule membrane protein 140kDa, antigen CD62)
Aliases	CD62; PSEL; PADGEM; GMP140; CD62P; GRMP; selectin P (granule membrane protein 140kD, antigen CD62); LECAM3; ......
Chromosomal Location	1q24.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell membrane Single-pass type I membrane protein
Domain	PF00059 Lectin C-type domain PF00084 Sushi repeat (SCR repeat)
Function	Ca(2+)-dependent receptor for myeloid cells that binds to carbohydrates on neutrophils and monocytes. Mediates the interaction of activated endothelial cells or platelets with leukocytes. The ligand recognized is sialyl-Lewis X. Mediates rapid rolling of leukocyte rolling over vascular surfaces during the initial steps in inflammation through interaction with SELPLG.

> Gene Ontology [ TOP ]
Biological Process	GO:0002237 response to molecule of bacterial origin GO:0002576 platelet degranulation GO:0002685 regulation of leukocyte migration GO:0002687 positive regulation of leukocyte migration GO:0006887 exocytosis GO:0007157 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0007159 leukocyte cell-cell adhesion GO:0007596 blood coagulation GO:0007599 hemostasis GO:0010543 regulation of platelet activation GO:0010572 positive regulation of platelet activation GO:0014065 phosphatidylinositol 3-kinase signaling GO:0014066 regulation of phosphatidylinositol 3-kinase signaling GO:0014068 positive regulation of phosphatidylinositol 3-kinase signaling GO:0019722 calcium-mediated signaling GO:0019932 second-messenger-mediated signaling GO:0030168 platelet activation GO:0030193 regulation of blood coagulation GO:0030194 positive regulation of blood coagulation GO:0030335 positive regulation of cell migration GO:0032496 response to lipopolysaccharide GO:0033622 integrin activation GO:0033623 regulation of integrin activation GO:0035584 calcium-mediated signaling using intracellular calcium source GO:0040017 positive regulation of locomotion GO:0042742 defense response to bacterium GO:0043254 regulation of protein complex assembly GO:0045055 regulated exocytosis GO:0045123 cellular extravasation GO:0048015 phosphatidylinositol-mediated signaling GO:0048017 inositol lipid-mediated signaling GO:0050817 coagulation GO:0050818 regulation of coagulation GO:0050820 positive regulation of coagulation GO:0050829 defense response to Gram-negative bacterium GO:0050865 regulation of cell activation GO:0050867 positive regulation of cell activation GO:0050878 regulation of body fluid levels GO:0050900 leukocyte migration GO:0050901 leukocyte tethering or rolling GO:0051272 positive regulation of cellular component movement GO:0061041 regulation of wound healing GO:0061756 leukocyte adhesion to vascular endothelial cell GO:0090303 positive regulation of wound healing GO:0098542 defense response to other organism GO:0098742 cell-cell adhesion via plasma-membrane adhesion molecules GO:1900046 regulation of hemostasis GO:1900048 positive regulation of hemostasis GO:1903034 regulation of response to wounding GO:1903036 positive regulation of response to wounding GO:2000147 positive regulation of cell motility
Molecular Function	GO:0001530 lipopolysaccharide binding GO:0001948 glycoprotein binding GO:0005539 glycosaminoglycan binding GO:0008201 heparin binding GO:0030246 carbohydrate binding GO:0031406 carboxylic acid binding GO:0033691 sialic acid binding GO:0042806 fucose binding GO:0043168 anion binding GO:0043208 glycosphingolipid binding GO:0046625 sphingolipid binding GO:0048029 monosaccharide binding GO:0048306 calcium-dependent protein binding GO:0051861 glycolipid binding GO:0070492 oligosaccharide binding GO:1901681 sulfur compound binding
Cellular Component	GO:0009897 external side of plasma membrane GO:0030141 secretory granule GO:0030659 cytoplasmic vesicle membrane GO:0030667 secretory granule membrane GO:0031088 platelet dense granule membrane GO:0031091 platelet alpha granule GO:0031092 platelet alpha granule membrane GO:0042827 platelet dense granule GO:0098552 side of membrane GO:0099503 secretory vesicle

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04514 Cell adhesion molecules (CAMs)
Reactome	R-HSA-202733: Cell surface interactions at the vascular wall R-HSA-109582: Hemostasis R-HSA-76002: Platelet activation, signaling and aggregation R-HSA-114608: Platelet degranulation R-HSA-76005: Response to elevated platelet cytosolic Ca2+

Summary
Symbol	SELP
Name	selectin P (granule membrane protein 140kDa, antigen CD62)
Aliases	CD62; PSEL; PADGEM; GMP140; CD62P; GRMP; selectin P (granule membrane protein 140kD, antigen CD62); LECAM3; ......
Chromosomal Location	1q24.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between SELP and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between SELP and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
17473183	Metastatic Melanoma	Promote immunity (infiltration)	Results show that the majority of metastatic melanoma samples examined do not express the vascular adhesion receptors E-selectin (CD62E), P-selectin (CD62P), and intercellular adhesion molecule-1 (CD54) on vessels within the tumor boundaries. This results in a block to recruitment of activated tumor-specific CTL to melanoma metastases and is a likely factor limiting the effectiveness of current immunotherapy protocols.
21926464	Melanoma	Promote immunity (infiltration)	Inflammatory cytokines such as IL-6 exert tumor-promoting activities by driving growth and survival of neoplastic cells. Mechanistically, IL-6 produced by nonhematopoietic stromal cells acted cooperatively with soluble IL-6 receptor-α and thermally induced gp130 to promote E/P-selectin- and ICAM-1-dependent extravasation of cytotoxic T cells in tumors.

Summary
Symbol	SELP
Name	selectin P (granule membrane protein 140kDa, antigen CD62)
Aliases	CD62; PSEL; PADGEM; GMP140; CD62P; GRMP; selectin P (granule membrane protein 140kD, antigen CD62); LECAM3; ......
Chromosomal Location	1q24.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of SELP in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	SELP
Name	selectin P (granule membrane protein 140kDa, antigen CD62)
Aliases	CD62; PSEL; PADGEM; GMP140; CD62P; GRMP; selectin P (granule membrane protein 140kD, antigen CD62); LECAM3; ......
Chromosomal Location	1q24.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of SELP in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.011	0.978
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.002	0.998
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.013	0.981
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.208	0.639
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.809	0.554
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.553	0.752
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.301	0.654
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.365	0.73
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.211	0.853
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.731	0.186
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.916	0.29
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.481	0.0459

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of SELP in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	4.1	-0.4	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	5.1	-1.4	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	9.5	0	9.5	0.492
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	0	7.7	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	12.5	-12.5	0.52
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	11.1	-11.1	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	14.3	-14.3	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	13.2	3.7	9.5	0.388
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	18.2	0	18.2	0.274
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	7.1	-0.9	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	SELP
Name	selectin P (granule membrane protein 140kDa, antigen CD62)
Aliases	CD62; PSEL; PADGEM; GMP140; CD62P; GRMP; selectin P (granule membrane protein 140kD, antigen CD62); LECAM3; ......
Chromosomal Location	1q24.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SELP. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	SELP
Name	selectin P (granule membrane protein 140kDa, antigen CD62)
Aliases	CD62; PSEL; PADGEM; GMP140; CD62P; GRMP; selectin P (granule membrane protein 140kD, antigen CD62); LECAM3; ......
Chromosomal Location	1q24.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SELP. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SELP. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	SELP
Name	selectin P (granule membrane protein 140kDa, antigen CD62)
Aliases	CD62; PSEL; PADGEM; GMP140; CD62P; GRMP; selectin P (granule membrane protein 140kD, antigen CD62); LECAM3; ......
Chromosomal Location	1q24.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SELP. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	SELP
Name	selectin P (granule membrane protein 140kDa, antigen CD62)
Aliases	CD62; PSEL; PADGEM; GMP140; CD62P; GRMP; selectin P (granule membrane protein 140kD, antigen CD62); LECAM3; ......
Chromosomal Location	1q24.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of SELP expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	SELP
Name	selectin P (granule membrane protein 140kDa, antigen CD62)
Aliases	CD62; PSEL; PADGEM; GMP140; CD62P; GRMP; selectin P (granule membrane protein 140kD, antigen CD62); LECAM3; ......
Chromosomal Location	1q24.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between SELP and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	SELP
Name	selectin P (granule membrane protein 140kDa, antigen CD62)
Aliases	CD62; PSEL; PADGEM; GMP140; CD62P; GRMP; selectin P (granule membrane protein 140kD, antigen CD62); LECAM3; ......
Chromosomal Location	1q24.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting SELP collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting SELP.

ID	Name	Drug Type	Targets	#Targets
DB01109	Heparin	Small Molecule	F10, FGF1, FGF19, FGF2, FGF4, FGFR1, FGFR2, FGFR4, HGF, PF4, SELP, ......	12
DB03721	N-acetyl-alpha-neuraminic acid	Small Molecule	AZGP1, CES1, MBL2, REG1A, SELE, SELP, SIGLEC1	7
DB06779	Dalteparin	Small Molecule	SELP, SERPINC1, TFPI, VEGFA	4
DB08813	Nadroparin	Small Molecule	FOS, MYC, SELP, SERPINC1	4

Browse SELP